CYTOSOL ACTIVATOR OF RAT RETICULOCYTE ADENYLATE CYCLASE
大鼠网状细胞腺苷酸环化酶的胞质激活剂
基本信息
- 批准号:3152193
- 负责人:
- 金额:$ 6.49万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1981
- 资助国家:美国
- 起止时间:1981-09-01 至 1989-08-31
- 项目状态:已结题
- 来源:
- 关键词:adenylate cyclase beta adrenergic agent cell membrane cholera toxin chromatography cytoplasm enzyme induction /repression erythrocyte membrane gel filtration chromatography guanine nucleotides hormone regulation /control mechanism human tissue isoproterenol lymphoma membrane activity monoclonal antibody neoplastic cell platelets radiotracer reticulocytes tissue /cell culture
项目摘要
The objective of this research project is to establish the identity,
mechanism of action, and importance of the cellular regulator of adenylate
cyclase obtained from the cytosol of rat reticulocytes. The reticulocyte
cytosol activator protein (RCAP), that augments catecholamine-sensitive
adenylate cyclase in rat reticulocyte membranes, has been only partially
purified and characterized. The goals of the research plan are to purify
and to completely characterize RCAP; to elucidate the mechanisms by which
it so profoundly influences catecholamine responsiveness; and to establish
to what extent, and by what means, RCAP regulates adenylate cyclase
activity in other tissues and species. RCAP will be purified to
homogeneity using established biochemical techniques including preparative
isoelectric focusing and other specific approaches outlined in Methods.
The mechanism of action of RCAP will be investigated by studies directed at
RCAP's effects upon each of the three components of the hormonal unit, the
beta-adrenergic receptor, the guanine nucleotide coupling protein, and the
catalytic unit of adenylate cyclase, as well as the interactions among
them. Specific methods will include radioligand binding studies,
determination of adenylate cyclase activity, and assessment of the guanine
nucleotide binding protein by means of the ADP-ribosylation assay. The
effects of RCAP upon other hormones that stimulate or inhibit adenylate
cyclase and in several other mammalian and tissues will also be
investigated in order to determine the importance of RCAP as a general
regulator of hormone action.
本研究项目的目标是建立身份,
作用机制和腺苷酸细胞调节剂的重要性
从大鼠网织红细胞的胞浆中获得的环化酶。 网织红细胞
胞质溶胶激活蛋白(RCAP),增强儿茶酚胺敏感性
腺苷酸环化酶在大鼠网织红细胞膜,一直只是部分
纯化和表征。 研究计划的目标是
并完全表征RCAP;阐明其机制,
它如此深刻地影响了儿茶酚胺的反应;并建立
在何种程度上,通过何种方式,RCAP调节腺苷酸环化酶
在其他组织和物种中的活性。 RCAP将被纯化,
使用已建立的生物化学技术,包括制备
等电聚焦和方法中概述的其他特定方法。
RCAP的作用机制将通过以下研究进行研究:
RCAP对激素单位的三个组成部分中的每一个的影响,
β-肾上腺素能受体,鸟嘌呤核苷酸偶联蛋白,和
腺苷酸环化酶的催化单位,以及
他们 具体方法包括放射性配体结合研究,
腺苷酸环化酶活性测定和鸟嘌呤
通过ADP-核糖基化测定的核苷酸结合蛋白。 的
RCAP对其他刺激或抑制腺苷酸的激素的影响
环化酶和其他几种哺乳动物和组织中也将被
调查,以确定RCAP作为一般的重要性,
激素作用的调节器。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Parathyroid hormone stimulates formation of inositol phosphates in a membrane preparation of canine renal cortical tubular cells.
甲状旁腺激素刺激犬肾皮质小管细胞膜制剂中磷酸肌醇的形成。
- DOI:10.1002/jbmr.5650050314
- 发表时间:1990
- 期刊:
- 影响因子:0
- 作者:Coleman,DT;Bilezikian,JP
- 通讯作者:Bilezikian,JP
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Elizabeth J Shane其他文献
Elizabeth J Shane的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Elizabeth J Shane', 18)}}的其他基金
Phase 2b Study of Denosumab to Prevent Bone Loss in Idiopathic Osteoporosis in Premenopausal Women Treated with Teriparatide
狄诺塞麦 (Denosumab) 预防接受特立帕肽治疗的绝经前妇女特发性骨质疏松症骨丢失的 2b 期研究
- 批准号:
9282269 - 财政年份:2016
- 资助金额:
$ 6.49万 - 项目类别:
Phase 2 Teriparatide for Tx of Idiopathic Osteoporosis in Premenopausal Women
特立帕肽治疗绝经前女性特发性骨质疏松症的 2 期临床试验
- 批准号:
8414605 - 财政年份:2011
- 资助金额:
$ 6.49万 - 项目类别:
Phase 2 Teriparatide for Tx of Idiopathic Osteoporosis in Premenopausal Women
特立帕肽治疗绝经前女性特发性骨质疏松症的 2 期临床试验
- 批准号:
8717112 - 财政年份:2011
- 资助金额:
$ 6.49万 - 项目类别:
Phase 2 Teriparatide for Tx of Idiopathic Osteoporosis in Premenopausal Women
特立帕肽治疗绝经前女性特发性骨质疏松症的 2 期临床试验
- 批准号:
8542495 - 财政年份:2011
- 资助金额:
$ 6.49万 - 项目类别:
Phase 2 Teriparatide for Tx of Idiopathic Osteoporosis in Premenopausal Women
特立帕肽治疗绝经前女性特发性骨质疏松症的 2 期临床试验
- 批准号:
8020203 - 财政年份:2011
- 资助金额:
$ 6.49万 - 项目类别:
Phase 2 Teriparatide for Tx of Idiopathic Osteoporosis in Premenopausal Women
特立帕肽治疗绝经前女性特发性骨质疏松症的 2 期临床试验
- 批准号:
8913676 - 财政年份:2011
- 资助金额:
$ 6.49万 - 项目类别:
Phase 2 Teriparatide for Tx of Idiopathic Osteoporosis in Premenopausal Women
特立帕肽治疗绝经前女性特发性骨质疏松症的 2 期临床试验
- 批准号:
8333235 - 财政年份:2011
- 资助金额:
$ 6.49万 - 项目类别:
Osteoporosis in HIV Infected Postmenopausal Women
感染艾滋病毒的绝经后妇女的骨质疏松症
- 批准号:
8100411 - 财政年份:2010
- 资助金额:
$ 6.49万 - 项目类别:
Osteoporosis in HIV Infected Postmenopausal Women
感染艾滋病毒的绝经后妇女的骨质疏松症
- 批准号:
8494520 - 财政年份:2010
- 资助金额:
$ 6.49万 - 项目类别:
Osteoporosis in HIV Infected Postmenopausal Women
感染艾滋病毒的绝经后妇女的骨质疏松症
- 批准号:
8011797 - 财政年份:2010
- 资助金额:
$ 6.49万 - 项目类别: